Diverse expression patterns and tumorigenic role of neurotensin signaling components in colorectal cancer cells
Authors:
Open Access
- 9 May 2017
- journal article
- research article
- Published by Spandidos Publications in International Journal of Oncology
- Vol. 50 (6) , 2200-2206
Abstract
Colorectal cancer (CRC), which is one of the most common malignancies worldwide, results from an accumulation of genetic and epigenetic modifications including DNA methylation. Neurotensin (NTS), a hormone localized to the gut and central nervous system, mediates its physiological and pathological effects, including growth stimulation for a variety of cancers, through three distinct NTS receptors (NTSRs). Most NTS functions are mediated through the high-affinity receptor NTSR1, and expression of NTSR1 is increased in many cancers including CRC. In this study, we investigated the expression profiles and cellular functions of the NTSRs, especially NTSR1, in CRC cells. We showed that expression levels for NTS and NTSR1 varied, that NTSR2 expression was not detectable and that NTSR3 was consistently expressed in all CRC cell lines examined. Treatment with the demethylating agent, 5-aza-2'-deoxycytidine, augmented levels of NTSR1/2 in Caco2 and DLD1 cells, which have little or no transcripts for NTSR1/2 suggesting that DNA methylation suppresses NTSR1/2 expression. In addition, we demonstrated that knockdown of NTSR1 decreased cell growth and migration in HCT116 and HT29 cells. Finally, we showed that treatment with SR48692, an antagonist of NTSR1, also inhibited cell proliferation and migration in the CRC cells. Our findings identify promoter methylation as an important process regulating the differential expression or silencing of NTSR1/2 in CRC cells. Moreover, inhibition of NTSR1 repressed tumorigenic effects in CRC cells, suggesting that NTSR1 may be used as a therapeutic target for CRC.Keywords
This publication has 29 references indexed in Scilit:
- Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapyFrontiers in Endocrinology, 2013
- The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancersBiochimie, 2011
- Interleukin‐8 is associated with proliferation, migration, angiogenesis and chemosensitivityin vitroandin vivoin colon cancer cell line modelsInternational Journal of Cancer, 2011
- Molecular Genetics of Colorectal CancerAnnual Review of Pathology: Mechanisms of Disease, 2011
- Neurotensin Receptor 1 Determines the Outcome of Non–Small Cell Lung CancerClinical Cancer Research, 2010
- The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer ProgressionPLOS ONE, 2009
- Identification of a novel therapeutic target for head and neck squamous cell carcinomas: A role for the neurotensin‐neurotensin receptor 1 oncogenic signaling pathwayInternational Journal of Cancer, 2008
- The in vitro influences of neurotensin on the motility characteristics of human U373 glioblastoma cellsNeuropathology and Applied Neurobiology, 2006
- Identification of 27 5′ CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancersOncogene, 2004
- Cell cycle targets of Ras/Raf signallingOncogene, 1998